C4a

Human (QC Testing)

研发参考(7) 1. Bokisch, VA, and HJ Muller-Eberhard. Anaphylatoxin inactivator of human plasma: Its isolation and characterization as a carboxypeptidase. J Clin Invest. 1970; 49:2427-36. (Biology). 2. Ember JA., Jagels MA., Hugli TE. Characterization of complement anaphylatoxins and their biological responses. In: J.E. Volanakis and M.M. Frank, ed. The human complement system in health and disease. Marcel Dekker, Inc; 1998:241-284. 3. Hugli, TE. Biochemistry and biology of anaphylatoxins. Complement . 1986; 3:108-110. (Biology). 4. Matsushita, M and T Fujita. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med. 1992; 176:1497-1502. (Biology). 5. Pfeifer PH, JJ Brehms, M Brunson, and TE Hugli 2000. Plasma C3a and C4a levels in liver transplant recipients: a longitudinal study. Immunopharmacology. 2000; 46:163-174. (Biology). 6. Pfeifer PH, Kawahara MS, Hugli TE. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem. 1999; 45(8):1190-1199. (Biology). 7. Porcel JM, J Ordi, A Castro-Salomo, et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol lmmunopathol. 1995; 74(3):283-8. (Biology).